- Home
- LCTX
as 02-21-2025 4:00pm EST
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 127.7M | IPO Year: | N/A |
| Target Price: | $4.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $1.61 | Next Earning Date: | 03-06-2025 |
| Revenue: | $8,719,000 | Revenue Growth: | -0.60% |
| Revenue Growth (this year): | -5.88% | Revenue Growth (next year): | 41.15% |
Stock Insider Trading Activity of Lineage Cell Therapeutics Inc. (LCTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | LCTX | Director10% Owner | Jan 27 '25 | Buy | $0.38 | 7,894,737 | $6,000,000.12 | 49,560,992 | |
| Howe Jill Ann | LCTX | Chief Financial Officer | Nov 26 '24 | Buy | $0.59 | 15,000 | $8,850.00 | 25,500 | |
| Samuel George A. III | LCTX | General Counsel | Nov 26 '24 | Buy | $0.60 | 15,000 | $9,000.00 | 22,184 |
Latest Lineage Cell Therapeutics Inc. News
LCTX Breaking Stock News: Dive into LCTX Ticker-Specific Updates for Smart Investing
Medical Device Network
10 days ago
Lineage begins study of OPC1 delivering device for spinal cord injury treatment
MT Newswires
11 days ago
Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury
Business Wire
11 days ago
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Business Wire
18 days ago
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Zacks
23 days ago
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Business Wire
a month ago
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Business Wire
2 months ago
Lineage Cell Therapeutics Issues Letter to Stockholders
TipRanks
2 months ago
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
Compare LCTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LCTX Lineage Cell Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.